Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > This is a gift

<< Previous

Bullboard Posts

Next >>

Comment by Riverfolkon Jul 16, 2021 2:18pm

132 Views

Post# 33560524

RE:This is a gift

I agree with you 100%, this technology if safe in humans and proven to have efficacy will have tremendous upside from here. Upside would change depending on Lung, Liver or Kidney.

current market cap $62,000,000 US

My short term target 400,000,000 US

$6.45 US roughly $7 Can

My medium target $12 Can

Long Term target $22 Can

Good luck to all